Mizolastine , ≥98% , 108612-45-9

CAS NO.：108612-45-9

Empirical Formula: C24H25FN6O

Molecular Weight: 432.49

MDL number: MFCD23140913

EINECS: 1308068-626-2

PRODUCT Properties

• Melting point: 217°
• Density: 1.34±0.1 g/cm3(Predicted)
• storage temp.: Refrigerator
• solubility: Chloroform (Slightly, Heated), DMSO, Methanol (Slightly, Heated)
• form: Solid
• pka: 9.73±0.40(Predicted)
• color: White
• Merck: 14,6221

Description and Uses

Mizolastine was marketed in Germany and Switzerland as Mizollen for the symptomatic relief of seasonal and perennial allergic rhinoconjunctivitis and urticaria. Mizolastine is a new long-acting, orally active antihistaminic agent with a rapid onset of action ; the two most recent H1 antagonists launched were fexofenadine, metabolite of terfenadine (Sepracor, 1996) and Olopatadine (Kyowa Hakko, 1997). Mizolastine can be prepared in 2 steps from 2-chloro 1- (4-fluorobenzyl)benzimidazole by successive condensations of appropriate amine and thioether. Mizolastine selectively blocks the peripheral H1 receptors (but not the serotonergic, noradrenergic, muscarinic receptors) with a minimal occupancy of brain receptors, and therefore does not elicit any sedative effects. Moreover, Mizolastine does not produce cardiac rhythm disorders which have been associated with certain non-sedating antihistamines in humans.

A highly selective histamine H1-receptor antagonist (with no anticholinergic, antiadrenergic, or antiserotonin activity) for use in the treatment of allergic disorders, especially rhinitis and urticaria.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H312-H332
• Precautionary statements: P280-P302+P352-P312-P322-P363-P501-P261-P271-P304+P340-P312-P264-P270-P301+P312-P330-P501
• RTECS: UW7481284
• HS Code: 2933.39.9200